# 2025-04021: FDA Awards Priority Voucher for Rare Kids' Disease Drug Gomekli

2025-04021, Issuance of Priority Review Voucher; Rare Pediatric Disease Product; Gomekli (mirdametinib), is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-03-13, effective 2025-02-11; PRIA reads it as touching household money (as of 2026-09-30).

- Canonical: https://policyrisk.com/federal-register/2025-04021
- As of: 2026-09-30
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-04021
- Title: Issuance of Priority Review Voucher; Rare Pediatric Disease Product; Gomekli (mirdametinib)
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 11992
- Published: 2025-03-13
- Effective: 2025-02-11
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-09-30

## In one line

FDA Awards Priority Voucher for Rare Kids' Disease Drug Gomekli

## Summary

The FDA just gave SpringWorks Therapeutics a special priority review voucher for their drug Gomekli, which treats a rare disease in kids and adults with neurofibromatosis type 1. This voucher speeds up future drug reviews, helping get important medicines to patients faster. The approval happened on February 11, 2025, marking a big win for rare disease treatments and innovation.

## Abstract

The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that GOMEKLI (mirdametinib), approved on February 11, 2025, manufactured by SpringWorks Therapeutics, Inc., meets the criteria for a priority review voucher.

## Effects PRIA read

- Gomekli approved for NF1 patients: benefit, high. GOMEKLI (mirdametinib) was approved on February 11, 2025. It is indicated for adults and pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas, expanding the set of approved treatment options for that patient group.
- Priority review voucher awarded to sponsor: benefit, medium. The FDA announced issuance of a priority review voucher under section 529 of the FD&C Act to the sponsor of the approved rare pediatric disease product, SpringWorks Therapeutics, Inc.; the notice is dated March 7, 2025 and references GOMEKLI's approval on February 11, 2025. The voucher award is for…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-04021 on federalregister.gov](https://www.federalregister.gov/documents/2025/03/13/2025-04021/issuance-of-priority-review-voucher-rare-pediatric-disease-product-gomekli-mirdametinib)
- [2025-04021 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-03-13/pdf/2025-04021.pdf)

## Related
- [Previous: 2025-04020, Determination That RIOMET (Metformin Hydrochloride) Oral Solution, 500 Milligra…](https://policyrisk.com/federal-register/2025-04020)
- [Next: 2025-04022, Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holdin…](https://policyrisk.com/federal-register/2025-04022)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-04021 (as of 2026-09-30).
